Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Latest Information Update: 25 Jul 2024
At a glance
- Drugs MB CART19.1 (Primary) ; MB-CART20.1 (Primary) ; Zamtocabtagene autoleucel (Primary)
- Indications Chronic lymphocytic leukaemia; Malignant melanoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms LONGSAFE
- Sponsors Miltenyi Biotec GmbH
Most Recent Events
- 25 Jul 2024 New trial record